Indian pharmaceutical firms go local for APIs, seeking to end reliance on China
Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end...
biocon
Biocon Biologics, Viatris receive EC approval for biosimilar insulin as part Kixelle
Biocon Biologics Ltd., a subsidiary of Bengaluru-headquartered Biocon Ltd., has announced that Kixelle, a biosimilar insulin as part co-developed with NASDAQ-listed Viatris Inc., has received...
Proposals for healthcare infra, Covid-19 vaccine allocation promising: Kiran Mazumdar Shaw
BENGALURU: The government’s proposals for the healthcare sector in the Union Budget 2021-22 would encourage more research and development (R&D), while an allocation of Rs.35000...
Biocon reports 17% drop in net profit, Christiane Hamacher steps down as MD of Biocon Biologics
BENGALURU: Biocon reported a near 17% decline in net profit to Rs 169 crore during the quarter to December, while the company’s topline grew 7%...
Oxford vaccine: Kiran Mazumdar-Shaw seeks quick regulatory processing after UK nod
Bengaluru: Biocon founder Kiran Mazumdar-Shaw on Tuesday sought quick processing of regulatory approvals in India for the AstraZeneca-Oxford vaccine after regulators in the UK cleared...
Kiran Mazumdar Shaw | Oxford vaccine: Kiran Mazumdar-Shaw seeks quick regulatory processing after UK nod
Bengaluru: Biocon founder Kiran Mazumdar-Shaw on Tuesday sought quick processing of regulatory approvals in India for the AstraZeneca-Oxford vaccine after regulators in the UK cleared...
India Inc fails to settle sexual harassment cases
Mumbai: Nearly seven years after the country enacted a law to prevent harassment of women at workplaces, several Indian companies still seem to be fumbling...
Biocon appoints Anupam Jindal as its Chief Financial Officer
BENGALURU: Biopharmaceuticals company Biocon Ltd has announced that Anupam Jindal has been appointed as its new Chief Financial Officer. Prior to joining the Bengaluru-headquartered company,...
Mylan, Biocon undercut insulin competitors on price with launch of Lantus copycat
After years of manufacturing woes torpedoed their chances to challenge Sanofi’s blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA’s go-ahead to launch...
Glargine launch in US opens up a huge opportunity for Biocon: Kiran Mazumdar Shaw
We are very excited that we have finally crossed the finishing line and we are now launching, says Executive Chairman, Biocon.You have launched glargine in...